No Data
No Data
Express News | Apellis And Sobi Announce Phase 3 VALIANT Study Results For Pegcetacoplan In Rare Kidney Diseases
Buy Rating Affirmed on Apellis Pharmaceuticals Amid Empaveli's Strong Clinical Outcomes and Market Potential
Express News | Apellis Pharmaceuticals Inc : Baird Raises Target Price to $96 From $86
Apellis Pharmaceuticals Shares Surge After Study Results
Sobi, Apellis' Rare Kidney Disease Drug Reduces Proteinuria in Late-Stage Study
Apellis Stock Jumps as Rare Kidney Disease Therapy Succeeds in Trial
No Data